



Why AREXVY?

AREXVY is a vaccine given as one single dose that helps to protect individuals against Respiratory Syncytial Virus (RSV) infection in adults aged 60 years and older, and adults 50 through 59 who are at increased risk for RSV disease.^{1,4}

RSV is highly contagious⁴

RSV is a highly contagious respiratory virus that causes infections of the lungs and breathing passages.⁴

How effective is AREXVY?

In a clinical trial conducted in 17 countries from the northern and southern hemispheres, a single dose of AREXVY demonstrated 62.9% overall efficacy in protecting against lower respiratory tract disease caused by RSV (RSV-LRTD) over 3 full RSV seasons in adults aged 60 years and older; median follow-up 30.6 months.^{1,18}

Over 3 RSV seasons^{1,18,20}

*A single dose of AREXVY showed 82.6% overall efficacy in protecting against RSV-LRTD in adults ≥60 years old during one RSV season (96.95% CI: 57.9 to 94.1); AREXVY, 7 cases out of 12,466; placebo, 40 cases out of 12,494; median follow-up 6.7 months.^{1,7}

¹A single dose of AREXVY demonstrated: 67.2% overall efficacy in protecting against RSV-LRTD over two RSV seasons in adults 60 years and older (97.5% CI, 48.2, 80.0); AREXVY (30 cases out of 12,469), placebo (139 cases out of 12,498); median follow-up 17.8 months.²⁰ 62.9% overall efficacy in protecting against RSV-LRTD over 3 full RSV seasons in adults aged 60 years and older (97.5% CI, 46.7, 74.8); AREXVY (48 cases out of 12,468), placebo (215 cases out of 12,498); median follow-up 30.6 months.¹⁸ **In this study, RSV seasons were defined as from 1 October to 30 April in the northern hemisphere and from 1 March to 30 September in the southern hemisphere.**¹⁸

CI=confidence interval

How much will AREXVY cost?

AREXVY is an unfunded vaccine for individuals 60 years of age and older, and adults 50 through 59 who are at increased risk of RSV disease.^{4,21} Please speak to your healthcare professional about expected costs.

Important safety information

As with any vaccine, vaccination with AREXVY can have side effects.^{1,4} AREXVY has benefits and risks¹ – ask your doctor if AREXVY is right for you.

Side effects of AREXVY include:^{1,4} itching, pain, redness or swelling at the injection site, fever, chills, tiredness, headache, muscle pain, joint pain, a runny nose, generally feeling unwell, nausea, stomach pain and swelling of the lymph nodes. This is not a full list.

If you need to, ask your doctor or pharmacist if you have any further questions about side effects.⁴

Do not use AREXVY if you are allergic to AREXVY, or any of its ingredients. Always check the ingredients to make sure you can receive this vaccine. If AREXVY is given at the same time as another vaccine, a different injection site will be used for each injection.⁴

Vaccination with AREXVY may not result in protection of all vaccine recipients.^{1,4}

References: 1. GlaxoSmithKline New Zealand. AREXVY Data Sheet. GSK NZ; 2025. Available at <https://www.medsafe.govt.nz/profs/datasheet/a/Arexvyninj.pdf> (Last accessed April 2026). 2. Mesa-Frias, M; J Manag Care Spec Phar; 2022;1-13. 3. CDC; 2023; RSV Transmission. <https://www.cdc.gov/rsv/causes/index.html> (Last Accessed February 2026). 4. GlaxoSmithKline New Zealand. AREXVY Consumer Medicine Information (CMI). GSK NZ; 2025 Available at <https://www.medsafe.govt.nz/consumers/cmi/a/Arexvy.pdf> (Accessed April 2026). 5. Kenmoe S, Nair H. et al., Curr Opin Infect Dis. 2024 Apr 1;37(2):129-136. 6. Walsh EE; Clinics in chest medicine; 2017; 38:29-36. 7. Papi A; N Engl J Med; 2023;388:595-608. 8. Branche AR; Clin Infect Dis; 2022;74:1004-1011. 9. CDC; 2025; 1-2; RSV in Adults, <https://www.cdc.gov/rsv/adults/index.html> (last accessed April 2026). 10. Nguyen-Van-Tam JS, et al. Eur Respir Rev. 2022;31(166):220105. 11. Wyffels V, et al. Adv Ther. 2020;37(3):1203-1217. 12. Schweitzer JW; NCBI Bookshelf; 2022;1-6. 13. Obando-Pacheco P; The Journal of Infectious Diseases; 2018;217:1356-1364. 14. Rose EB; MMWR Morb Mortal Wkly Rep; 2018;67:71-76. 15. Immunisation Advisory Centre; 2024; 1-3; Respiratory syncytial virus (RSV). 16. ESR; 2022; 2022 ACUTE RESPIRATORY ILLNESS SURVEILLANCE REPORT 17. CDC; 2022; 1-2; RSV in Older Adults and Adults with Chronic Medical Conditions. 18. Ison MG; Lancet Respir Med; 2025; 13(6):517-529. 19. CDC.gov; 2025; 1-3; Respiratory Syncytial Virus Infection. 20. Ison MG; Clinical Infectious Diseases; 2024; 1-29. 21. Health NZ; Immunisation Handbook; 2026; 1-695

AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older, and in adults 50 through 59 years of age who are at increased risk of RSV disease. AREXVY is a prescription medicine; it is not funded and charges will apply. A single dose (0.5 mL) contains 120 micrograms of RSVPreF3 antigen adjuvanted with AS01E, composed of the plant extract *Quillaja saponaria* Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from *Salmonella minnesota* (25 micrograms). AREXVY should not be administered if you are allergic to any component of this vaccine. AREXVY has risks and benefits – ask your doctor if AREXVY is right for you. Use strictly as directed. Side effects include: joint pain, injection site reactions including pain, swelling and redness, headache, runny nose, fatigue, fever and chills. This is not a full list. Vaccination with AREXVY may not fully protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's charges apply. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.

TAPS NP24552 PM-NZ-RSA-BROC-260002

Date of Approval: 04 2026

Date of Expiry: 04 2028

For New Zealand residents only



RSV?

AREXVY is a vaccine for eligible older adults¹

What?

RSV is a contagious respiratory virus.²⁻⁴ It can lead to severe infections affecting the lungs and lower airways.²⁻⁴

Who?

It can cause serious respiratory illnesses and complications in older adults, including those with certain underlying medical conditions.²⁻⁵

How?

RSV spreads easily via coughing and sneezing.²⁻⁴

¹ AREXVY is indicated for adults 60 years of age and older and adults 50-59 years of age who are at increased risk for RSV disease.^{1,4}

Help protect against RSV⁴ with

AREXVY

Patient portrayal



